/IOVA
IOVA Stock - Iovance Biotherapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$2.48+0.81%
+$0.02 (+0.81%) • Dec 19
79
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.66
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.87
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+108.5%upside
Target: $5.17
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IOVA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.46 – $2.50
TARGET (TP)$5.17
STOP LOSS$2.28
RISK/REWARD1:13.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.83
52W High$8.15
52W Low$1.64
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $164.07M | $1.19M | N/A | N/A | N/A |
| Gross Profit | $40.08M | $-9,566,000 | N/A | N/A | N/A |
| Gross Margin | 24.4% | -804.5% | N/A | N/A | N/A |
| Operating Income | $-395,278,000 | $-460,559,000 | $-398,878,000 | $-342,703,000 | $-261,937,000 |
| Net Income | $-372,177,000 | $-444,037,000 | $-395,893,000 | $-342,252,000 | $-259,581,000 |
| Net Margin | -226.8% | -37345.4% | N/A | N/A | N/A |
| EPS | $-1.28 | $-1.89 | $-2.49 | $-2.23 | $-1.88 |
Company Overview
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
20%
Hold / Neutral
7
70%
Sell / Underperform
1
10%
Analyst Consensus🔴 Bearish
2 Bullish8 Neutral/Bearish
Price Targets
$11
Average Target
↑ 347.2% Upside
Now
$1
Low
$11
Average
$18
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 15th 2025 | Goldman | Downgrade | Sell | $1 |
| May 16th 2025 | UBS | Downgrade | Neutral | $2 |
| May 12th 2025 | Truist | Downgrade | Hold | - |
| May 9th 2025 | Citizens JMP | Downgrade | Market Perform | - |
| October 24th 2024 | UBS | Initiation | Buy | $17 |
| July 29th 2024 | Piper Sandler | Downgrade | Neutral | $10← $19 |
| November 20th 2023 | Goldman | Initiation | Buy | $12 |
| September 18th 2023 | Barclays | Reiterated | Overweight | $18← $40 |
| May 30th 2023 | Wells Fargo | Upgrade | Overweight | $17← $11 |
| March 27th 2023 | Wells Fargo | Resumed | Equal Weight | $11 |
| January 27th 2023 | Piper Sandler | Upgrade | Overweight | $14← $11 |
| December 9th 2022 | Goldman | Downgrade | Neutral | $6← $20 |
| October 31st 2022 | Guggenheim | Initiation | Neutral | - |
| August 18th 2022 | Wells Fargo | Resumed | Equal Weight | $14 |
Earnings History & Surprises
IOVABeat Rate
44%
Last 18 quarters
Avg Surprise
+2.6%
EPS vs Estimate
Beats / Misses
8/7
3 met exactly
Latest EPS
$-0.25
Q4 2025
EPS Surprise History
Q1 24
-2.3%
$-0.45vs$-0.44
Q2 24
+6.7%
$-0.42vs$-0.45
Q3 24
+8.1%
$-0.34vs$-0.37
Q4 24
+9.7%
$-0.28vs$-0.31
Q1 25
0.0%
$-0.26vs$-0.26
Q2 25
-44.0%
$-0.36vs$-0.25
Q3 25
-13.8%
$-0.33vs$-0.29
Q4 25
+13.8%
$-0.25vs$-0.29
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 26, 2026 | $-0.22 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.29 | $-0.25 | +13.8% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.29 | $-0.33 | -13.8% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.25 | $-0.36 | -44.0% | ✗ MISS |
Q1 2025 | Feb 27, 2025 | $-0.26 | $-0.26 | 0.0% | = MET |
Q4 2024 | Nov 7, 2024 | $-0.31 | $-0.28 | +9.7% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.37 | $-0.34 | +8.1% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.45 | $-0.42 | +6.7% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $-0.44 | $-0.45 | -2.3% | ✗ MISS |
Q4 2023 | Nov 7, 2023 | $-0.46 | $-0.46 | 0.0% | = MET |
Q3 2023 | Aug 8, 2023 | $-0.81 | $-0.47 | +42.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.84 | $-0.50 | +40.5% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-0.64 | $-0.64 | 0.0% | = MET |
Q4 2022 | Nov 3, 2022 | $-0.64 | $-0.63 | +1.6% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.60 | $-0.63 | -5.0% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.64 | $-0.58 | +9.4% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.56 | $-0.63 | -12.5% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.52 | $-0.55 | -5.8% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $-0.52 | $-0.53 | -1.9% | ✗ MISS |
Latest News
Iovance Biotherapeutics shares are trading higher after Barclays raised the price target from $9 to $10.
📈 PositiveBenzinga•Dec 17, 2025, 05:59 PM•Also:
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $10
📈 PositiveBenzinga•Dec 17, 2025, 05:45 PM•Also:
Iovance Biotherapeutics shares are trading higher after Barcays maintained an Overweight rating on the stock and raised its price target from $4 to $9.
📈 PositiveBenzinga•Nov 24, 2025, 04:19 PM
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $9
📈 PositiveBenzinga•Nov 24, 2025, 02:30 PM•Also:
Chardan Capital Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $17
📈 PositiveBenzinga•Nov 6, 2025, 11:06 PM
Iovance rises 34% as Q3 bottom line beat supported by strong Amtagvi sales
📈 PositiveSeeking Alpha•Nov 6, 2025, 07:03 PM
Iovance Biotherapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results and issued FY25 sales guidance with its midpoint above estimates.
📈 PositiveBenzinga•Nov 6, 2025, 01:50 PM
Iovance Biotherapeutics Affirms FY2025 Sales Guidance of $250.000M-$300.000M vs $264.918M Est
➖ NeutralBenzinga•Nov 6, 2025, 01:01 PM
Iovance Biotherapeutics Q3 EPS $(0.25) Beats $(0.26) Estimate, Sales $67.455M Miss $72.402M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 01:00 PM
Iovance Biotherapeutics' Interim Data From Phase 2 IOV-LUN-202 Trial Of Lifileucel Monotherapy For Previously Treated Patients With Advanced Nonsquamous Nsclc Without Actionable Genetic Mutations Showed 26% Objective Response Rate
📈 PositiveBenzinga•Nov 3, 2025, 12:03 PM
HC Wainwright & Co. Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $9
➖ NeutralBenzinga•Oct 29, 2025, 05:38 PM
Iovance Biotherapeutics Enters Amended Sale Agreement With Jefferies; May Sell Up To $350M Of Common Stock
➖ NeutralBenzinga•Aug 22, 2025, 09:23 PM
Iovance Biotherapeutics shares are trading higher after the company announced it received a Health Canada Notice of Compliance with Conditions for Amtagvi.
📈 PositiveBenzinga•Aug 19, 2025, 12:54 PM
HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $20 Price Target
📈 PositiveBenzinga•Aug 19, 2025, 11:06 AM
Iovance gets conditional Health Canada approval for Amtagvi
📈 PositiveSeeking Alpha•Aug 18, 2025, 09:00 PM
Iovance Biotherapeutics Receives Health Canada NOC/c For Amtagvi
📈 PositiveBenzinga•Aug 18, 2025, 08:24 PM
Iovance falls after missing Q2 expectation
📉 NegativeSeeking Alpha•Aug 8, 2025, 07:48 PM
Iovance climbs after FDA rejection for Replimune's skin cancer drug
📈 PositiveSeeking Alpha•Jul 22, 2025, 02:54 PM
Iovance falls after guidance cut, revenue miss
📉 NegativeSeeking Alpha•May 9, 2025, 04:01 PM
Frequently Asked Questions about IOVA
What is IOVA's current stock price?
Iovance Biotherapeutics, Inc. (IOVA) is currently trading at $2.48 per share. The stock has moved +0.81% today.
What is the analyst price target for IOVA?
The average analyst price target for IOVA is $5.17, based on 1 analyst.
What sector is Iovance Biotherapeutics, Inc. in?
Iovance Biotherapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is IOVA's market cap?
Iovance Biotherapeutics, Inc. has a market capitalization of $0.82 billion, making it a small-cap company.
Does IOVA pay dividends?
No, Iovance Biotherapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATXS
Astria Therapeutics, Inc.
$12.83
Mkt Cap: $0.7B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
CTMX
CytomX Therapeutics, Inc.
$4.00
Mkt Cap: $0.7B
DNA
Ginkgo Bioworks Holdings, Inc.
$8.10
Mkt Cap: $0.4B
ERAS
Erasca, Inc.
$3.45
Mkt Cap: $1.0B
MBX
MBX Biosciences, Inc. Common Stock
$30.42
Mkt Cap: $1.0B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
MLTX
MoonLake Immunotherapeutics
$13.39
Mkt Cap: $0.9B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
VIR
Vir Biotechnology, Inc.
$5.76
Mkt Cap: $0.8B
Explore stocks similar to IOVA for comparison